4C-D (Ariadne) is a rare psychedelic phenethylamine first synthesized by Alexander Shulgin in 1968. It was developed by Bristol Laboratories and reached phase 3 clinical trials as an antidepressant and motivational enhancer before being discontinued for economic reasons. Unlike typical psychedelics, 4C-D produces minimal hallucinogenic effects even at high doses, instead causing mental alertness, mood enhancement, and mild stimulation.
Perspectives
“I believe that my mood has distinctly improved, and my sleep that evening was excellent. This is physically benign.”
Build-updevelops over days to weeks of regular use
Reset3β7 days for acute; 1β3 weeks for full reset
Tolerance Decay
Full tolerance
1dHalf tolerance
3dBaseline
~7d
Pattern assumed similar to other serotonergic psychedelics: rapid short-term tolerance that decays over ~1β2 weeks. Evidence quality is low and based on analogy plus limited user reports.